The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Methods Matter -- Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors
Open accessPreprint — published as 10.1016/j.omtm.2020.05.018
Abstract
Different manufacturing approaches have been used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Sf9 insect cells. Unexplained differences in vector performance have been seen clinically and preclinically. Thus, we performed for the first time a highly controlled comparative production analysis varying only the host cell species but keeping all other rAAV production parameters the same. We demonstrate that host cell species is critical for determining vector potency. Given these key findings, we then sought to deeply characterize differences in rAAVs when produced by these two manufacturing platforms with multiple analytical approaches including: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM, denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and comparative functional transduction assessments in vitro and in vivo , including in humanized liver mice. Using these tools we’ve made two major discoveries: 1) rAAV capsids have post-translational modifications (PTMs) including glycosylation, acetylation, phosphorylation, methylation and deamidation, and these PTMs differ between platforms; 2) rAAV genomes are methylated during production, and these methylation marks are also differentially deposited between platforms. In addition, our data also demonstrate that host cell protein impurities differ between platforms and can have their own PTMs including potentially immunogenic N-linked glycans. We show that human-produced rAAVs are more potent than baculovirus- Sf9 vectors in various cell types in vitro ( P < 0.05-0.0001), in various mouse tissues in vivo ( P < 0.03-0.0001), and in human liver in vivo ( P < 0.005). Collectively, our findings were reproducible across vendors, including commercial manufacturers, academic core facilities, and individual laboratory preparations. These vector differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity as well as cost considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 3 Packaged rAAV Genomes Are Methylated during Production and Differentially Methylated Based on the Manufacturing Platform The five tracks of the Circos plot from the outside-in represent the following. First, a schematic of the ssAAV8 genome sequenced with key features labeled is shown (inverted terminal repeat [ITR], orange; intervening sequences, gray; EF1α promoter, red; firefly luciferase expression cassette, blue; woodchuck hepatitis virus posttranscriptional regulatory element [WPRE], plum; human growth hormone polyadenylation signal [hGHpA], magenta). Second, in blue, the methylation ratios for all detected sites for baculovirus-Sf9-produced rAAV8 are shown; the plotting represents a minimum of 0 and a maximum of 1 in 0.1 increments. Third, in red, the methylation ratios for all detected sites for human-produced rAAV are shown; scale same as previous. Fourth, in blue, the total numbers of reads at detected sites for baculovirus-Sf9 produced rAAV8 are shown; in log2 scale, from a minimum of 0 (total reads of 1) to a maximum of 11 (total reads of 211), in 0.1 increments. Fifth, in red, the total numbers of reads at detected sites for human-produced rAAV are shown; scale same as previous. The three sites with statistically significant differential methylation are highlighted in green (C:1208, C:2970, C:3779).](https://figures.cochat.ai/paper-figures/78bbfdddd3c14dd6ad0c41c22c28e3ac/methods-matter-standard-production-platforms-for-recombinant-aav-produce-figure-3.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It showed that the rAAV capsids can have post-translational modifications, such as glycosylation, that depend on the species origin of the production cell.”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rAAVs produced in a human cell line (HEK293T) compared to baculovirus-Sf9 produced rAAVs were more potent in transfecting the liver in mice in vivo and in vitro (HEK293T, Huh7, human induced Pluripotent Stem Cells (hiPSCs), primary human fibroblasts, mouse C2C12 cells).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“The rAAV production cell line and production cell line related impurities can influence the transduction efficiency in target tissue [44] (Sections 2 and 4.4).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Circos: An information aesthetic for comparative genomics
Krzywinski, M., Schein, J., Birol, İ., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 10,964
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
ImageJ2: ImageJ for the next generation of scientific image data
Rueden, C. T., Schindelin, J., Hiner, M. C., DeZonia, B. E., Walter, A. E., Arena, E. T., & Eliceiri, K. W. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1934-z · Cited by 5,980
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Research works printed but not linked: 3
- https://investors.biomarin.com/2019-01-07-BioMarin-Highlights-Key-Milestones-for-2019-at-37th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco.
- https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy.
- 2013, Phenix.real_space_refine, Computational Crystallography Newsletter, 4, 43
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors
Tan, E., Chin, C. S. H., Lim, Z. F. S., & Ng, S. K. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.796991 · Cited by 251
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Successes and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 184
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Adeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
AAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Barnes, L. F., Draper, B. E., Chen, Y., Powers, T. W., & Jarrold, M. F. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.08.002 · Cited by 92
Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing
Fu, Q., Polanco, A., Lee, Y. S., & Yoon, S. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28412 · Cited by 93
Dobrowsky, T., Gianni, D., Pieracci, J., & Suh, J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100353 · Cited by 90
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Analytical characterization of full, intermediate, and empty AAV capsids
McColl-Carboni, A., Dollive, S., Laughlin, S., Lushi, R., MacArthur, M., Zhou, S., Gagnon, J., Smith, C. A., Burnham, B. L., Horton, R., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00444-2 · Cited by 89
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
Ebberink, E. H. T. M., Ruisinger, A., Nuebel, M., Thomann, M., & Heck, A. J. R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.11.003 · Cited by 68
Guo, J., Kufer, R., Li, D., Wohlrab, S., Greenwood‐Goodwin, M., & Yang, F. (2023) · mAbs · doi:10.1080/19420862.2023.2213365 · Cited by 65
Joshi, P. R. H., Venereo-Sánchez, A., Chahal, P. S., & Kamen, A. (2020) · Biotechnology Journal · doi:10.1002/biot.202000021 · Cited by 64
Characterization of AAV vectors: a review of analytical techniques and critical quality attributes
Kontogiannis, T., Braybrook, J., McElroy, C., Foy, C., Whale, A. S., Quaglia, M., & Smales, C. M. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101309 · Cited by 57
Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain
Simpson, B. P., Yrigollen, C. M., Izda, A., & Davidson, B. L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.004 · Cited by 56
Liu, S., Li, J., Peraramelli, S., Luo, N., Chen, A., Dai, M., Liu, F., Yu, Y., Leib, R. D., Li, Y., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.022 · Cited by 56
Self-citationRoctavian gene therapy for hemophilia A
Samelson‐Jones, B. J., Small, J. C., & George, L. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011847 · Cited by 58
Assessment of quality attributes for adeno‐associated viral vectors
Tustian, A. D., & Bak, H. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27905 · Cited by 55
Handyside, B., Ismail, A. M., Zhang, L., Yates, B., Xie, L. Y., Sihn, C., Murphy, R., Bouwman, T., Kim, C. K., Angelis, R. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.001 · Cited by 54
Gorovits, B., Azadeh, M., Buchlis, G., Harrison, T., Havert, M., Jawa, V., Long, B., McNally, J., Milton, M., Nelson, R., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00628-3 · Cited by 53
Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia
Pierce, G. F., Fong, S., Long, B. R., & Kaczmarek, R. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.12.005 · Cited by 50
Cryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Development of Stable Packaging and Producer Cell Lines for the Production of AAV Vectors
Merten, O. (2024) · Microorganisms · doi:10.3390/microorganisms12020384 · Cited by 47
AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion
Kim, J.-J., Kurial, S. N. T., Choksi, P. K., Nunez, M., Lunow-Luke, T., Bartel, J., Driscoll, J., Her, C. L., Dhillon, S., Yue, W., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02523-6 · Cited by 47
Gene Therapy: It Is Time to Talk about High-Dose AAV
Paulk, N. K. (2020) · Genetic Engineering & Biotechnology News · doi:10.1089/gen.40.09.04 · Cited by 47
Self-citationAnalysis of AAV-Extracted DNA by Charge Detection Mass Spectrometry Reveals Genome Truncations
Barnes, L. F., Draper, B. E., Kurian, J. J., Chen, Y., Shapkina, T., Powers, T. W., & Jarrold, M. F. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04234 · Cited by 47
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
Safety questions for AAV gene therapy
Venditti, C. P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00756-9 · Cited by 46
Zhang, X., Jin, X., Liu, L., Zhang, Z., Koza, S. M., Yu, Y. Q., & Chen, W. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.046 · Cited by 45
Wada, M., Uchida, N., Posadas-Herrera, G., Hayashita‐Kinoh, H., Tsunekawa, Y., Hirai, Y., & Okada, T. (2023) · Gene Therapy · doi:10.1038/s41434-023-00398-x · Cited by 44
Adeno-associated virus vectors and neurotoxicity—lessons from preclinical and human studies
Stone, D., Aubert, M., & Jerome, K. R. (2023) · Gene Therapy · doi:10.1038/s41434-023-00405-1 · Cited by 44
The downstream bioprocess toolbox for therapeutic viral vectors
Kilgore, R., Minzoni, A., Shastry, S., Smith, W. K., Barbieri, E., Wu, Y., LeBarre, J. P., Chu, W., O'Brien, J., & Menegatti, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464337 · Cited by 41
Differential T cell immune responses to deamidated adeno-associated virus vector
Bing, S. J., Justesen, S. F. L., Wu, W. W., Sajib, A. M., Warrington, S., Baer, A., Thorgrimsen, S., Shen, R., & Mazor, R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.005 · Cited by 40
Orbitrap-Based Mass and Charge Analysis of Single Molecules
Deslignière, E., Rolland, A. D., Ebberink, E. H. T. M., Yin, V. C., & Heck, A. J. R. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00079 · Cited by 39
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
Bracewell, D. G., Smith, V., Delahaye, M., & Smales, C. M. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.06.026 · Cited by 35
Peptide ligands for the affinity purification of adeno‐associated viruses from HEK 293 cell lysates
Chu, W., Shastry, S., Barbieri, E., Prodromou, R., Greback‐Clarke, P., Smith, W. K., Moore, B., Kilgore, R., Cummings, C., Pancorbo, J., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28495 · Cited by 35
AAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Gene therapy: challenges in cell culture scale-up
Shupe, J., Zhang, A., Odenwelder, D. C., & Dobrowsky, T. M. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102721 · Cited by 32
Shmidt, A. A., & Egorova, T. V. (2021) · Pharmaceuticals · doi:10.3390/ph15010023 · Cited by 30
AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities
Kabadi, A. M., Mejía‐Guerra, M. K., Graef, J. D., Khan, S. Z., Walton, E. M., Wang, X., Gersbach, C. A., & Potter, R. A. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100517 · Cited by 29
Green, E. A., & Lee, K. H. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.06.025 · Cited by 28
Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard
Mietzsch, M., Liu, W., Ma, K., Bennett, A. D., Nelson, A. R., Gliwa, K., Chipman, P. R., Fu, X., Bechler, S. L., McKENNA, R. V., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.002 · Cited by 30
Bucher, K., Rodríguez‐Bocanegra, E., Wissinger, B., Straßer, T., Clark, S. J., Birkenfeld, A. L., Siegel-Axel, D. I., & Fischer, M. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-28830-7 · Cited by 28
Lu, M., Lee, Z., Lin, Y., Irfanullah, I., Cai, W., & Hu, W. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28562 · Cited by 26
Polyethylene glycol precipitation: fundamentals and recent advances
Royo, M. D. C. P., & Jungbauer, A. (2025) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2025.2470220 · Cited by 24
Trivedi, P. D., Yu, C., Chaudhuri, P., Johnson, E. J., Caton, T., Adamson-Small, L. A., Byrne, B. J., Paulk, N. K., & Clément, N. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.12.006 · Cited by 24
Self-citationrAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing
Iglesias, C. F., Ristovski, M., Bolić, M., & Čuperlović‐Culf, M. (2023) · Bioengineering · doi:10.3390/bioengineering10020229 · Cited by 24
Current avenues of gene therapy in Pompe disease
Leon‐Astudillo, C., Trivedi, P. D., Sun, R. C., Gentry, M. S., Fuller, D. D., Byrne, B. J., & Corti, M. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001187 · Cited by 24
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 24
Lorek, J. K., Isaksson, M., & Nilsson, B. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28932 · Cited by 24
Rieser, R., Penaud‐Budloo, M., Bouzelha, M., Rossi, A., Menzen, T., Biel, M., Büning, H., Ayuso, E., Winter, G., & Michalakis, S. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.031 · Cited by 24
Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy
Kowshik, N. C. S. S., & Singh, P. (2025) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2025.1709095 · Cited by 24
Giles, A. R., Lock, M. W., Chen, S., Turner, K. B., Wesolowski, G. A., Prongay, A., Petkov, B., Olagbegi, K., Yan, H., & Wilson, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.116 · Cited by 23
Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis
Serrano, M. A. C., Furman, R., Chen, G., & Tao, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103442 · Cited by 22
Wright, J. F. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.004 · Cited by 20
Engineered CHO cells as a novel AAV production platform for gene therapy delivery
Nagy, A., Chakrabarti, L., Kurasawa, J. H., Mulagapati, S. H. R., Devine, P., Therres, J., Chen, Y., & Schmelzer, A. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-46298-3 · Cited by 19
Engineered nanoparticles promote cardiac tropism of AAV vectors
Switala, L. E., Di, L., Gao, H., Asase, C., Klos, M., Palanivel, R., Fedyukina, D. V., & Maiseyeu, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02485-6 · Cited by 19
Advances and opportunities in process analytical technologies for viral vector manufacturing
Sripada, S. A., Hosseini, M., Ramesh, S., Wang, J., Ritola, K., Menegatti, S., & Daniele, M. A.-A. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108391 · Cited by 19
Rumachik, N. G., Malaker, S. A., & Paulk, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657795 · Cited by 19
Self-citationProbing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry
Ebberink, E. H. T. M., Ruisinger, A., Nuebel, M., Meyer‐Berg, H., Ferreira, I. R. S., Thomann, M., & Heck, A. J. R. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101293 · Cited by 18
Lu, M., Lee, Z., & Hu, W. (2024) · Biotechnology Progress · doi:10.1002/btpr.3428 · Cited by 18
Partial genome content within rAAVs impacts performance in a cell assay-dependent manner
Troxell, B., Jaslow, S. L., Tsai, I.-W., Sullivan, C. S., Draper, B. E., Jarrold, M. F., Lindsey, K., & Blue, L. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.007 · Cited by 17
Therapeutic Application and Structural Features of Adeno-Associated Virus Vector
Matsuzaka, Y., & Yashiro, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080499 · Cited by 16
Host cell protein-mediated adjuvanticity and immunogenicity risks of biotherapeutics
Panikulam, S., Morgan, H., Gutknecht, M., Villiger, T. K., Lebesgue, N., & Karle, A. C. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108575 · Cited by 16
Morris, J. A., Boshoff, C. H., Schor, N. F., Wong, L. M., Gao, G., & Davidson, B. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.010 · Cited by 16
Stronger together: Analytical techniques for recombinant adeno associated virus
Hutanu, A., Boelsterli, D., Schmidli, C., Montealegre, C., Thai, M. H. N. D., Bobály, B., Koch, M., & Schwarz, M. A. (2021) · Electrophoresis · doi:10.1002/elps.202100302 · Cited by 15
Thermostability and in vivo performance of AAV9 in a film matrix
Doan, T. N. K., Le, M. D., Bajrovic, I., Celentano, L., Krause, C., Balyan, H. G., Svancarek, A., Mote, A., Tretiakova, A. P., Samulski, R. J., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00212-6 · Cited by 15
Advancing AAV production with high-throughput screening and transcriptomics
Reid, C. A., Hörer, M., & Mandegar, M. A. (2024) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2024.095 · Cited by 14
Leibiger, T. M., Min, L., & Lee, K. H. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101383 · Cited by 14
SP3-based host cell protein monitoring in AAV-based gene therapy products using LC-MS/MS
Smith, J., Strasser, L., Guapo, F., Milian, S. G., Snyder, R. O., & Bones, J. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.06.019 · Cited by 14
Measurement of Adenovirus-Based Vector Heterogeneity
Hickey, J. M., Jacob, S. I., Tait, A. S., Dastjerdi, F. V., Barritt, J. D., Rouse, S. L., Douglas, A. D., Joshi, S. B., Volkin, D. B., & Bracewell, D. G. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.012 · Cited by 14
Som, M., Gikanga, B., Kanapuram, V., & Yadav, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.024 · Cited by 13
Overview of analytics needed to support a robust gene therapy manufacturing process
Ramsey, J. P., Khatwani, S. L., Lin, M. J., Boregowda, R., Surosky, R. T., & Ramelmeier, R. A. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100339 · Cited by 12
Ikeda, T., Yamaguchi, Y., Oyama, H., Matsushita, A., Tsunaka, Y., Fukuhara, M., Torisu, T., & Uchiyama, S. (2024) · Viruses · doi:10.3390/v16040585 · Cited by 12
Glycosylation of recombinant adeno-associated virus serotype 6
Yamaguchi, Y., Ishii, K., Koizumi, S., Sakaue, H., Maruno, T., Fukuhara, M., Shibuya, R., Tsunaka, Y., Matsushita, A., Bandoh, K., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101256 · Cited by 11
Lee, Z., Lu, M., Irfanullah, E., Soukup, M., Schmidt, D., & Hu, W. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.001 · Cited by 11
Zhao, W., Luo, J., Wang, F., Shi, Y., Zhang, J., Zhang, Y., Li, Y., Wang, X., Chen, Y., Zhang, X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.015 · Cited by 10
Analysis of Host Cell Proteins in AAV Products with ProteoMiner Protein Enrichment Technology
Zhang, S., Xiao, H., & Li, N. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03884 · Cited by 10
Wu, Y., Han, Z., Duan, M., Jiang, L., Tian, T., Jin, D., Wang, Q., & Xu, F. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210118111657 · Cited by 10
Gurazada, S. G. R., Kennedy, H. M., Braatz, R. D., Mehrman, S. J., Polson, S. W., & Rombel, I. T. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108506 · Cited by 9
Zarei, M., Wang, P., Jonveaux, J., Haller, F. M., Gu, B., Koulov, A. V., & Jahn, M. (2021) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9247 · Cited by 9
Roach, M. K., Wirz, P., Rouse, J. L., Schorzman, A., Beard, C. W., & Scott, D. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101320 · Cited by 9
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
Pipe, S. W., Arruda, V. R., Lange, C., Kitchen, S., Eichler, H., & Wadsworth, S. C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220914105729 · Cited by 9
Leibiger, T. M., Min, L., & Lee, K. H. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1579098 · Cited by 8
Seitz, I. P., Rodríguez‐Bocanegra, E., Bucher, K., Reichel, F. F., Michalakis, S., Romanovsky, D., Biel, M., Wissinger, B., Bartz‐Schmidt, K. U., Peters, T. M., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.38 · Cited by 8
A clinician’s guide to AAV production – How manufacturing platforms shape vector properties
Käsbach, J., & Magnus, J. B. (2025) · Medizinische Genetik · doi:10.1515/medgen-2025-2024 · Cited by 8
Hoyle, B., Hill, J., & Bello, D. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01194-8 · Cited by 8
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products
Mann, C. J., Giblin, J., Braun, M., Schmid, F., Sørensen, M. R., Caferra, P., Hudák, A., Letoha, T., Coderch, N., Hickling, T. P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102422 · Cited by 7
Meierrieks, F., Rosario, J.-C., Rübeling, L., Asikoglu, H. C., Pflanz, K. B., Pickl, A., Kusch, K., Wolff, M. W., & Graf, B. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465674 · Cited by 7
Zarei, M., Jonveaux, J., Wang, P., Haller, F. M., Gu, B., Koulov, A. V., & Jahn, M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05325 · Cited by 7
Metadata
- Authors
- Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., Sinn, P., May, A. P., & Paulk, N. K.
- Affiliations
- Stanford University (US)
- University of California, San Francisco (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Cold Spring Harbor Laboratory (US)
- University of Iowa (US)
- Corresponding author
- Paulk, Nicole K.
- ORCID
- Venue
- Molecular Therapy — Methods & Clinical Development
- Publisher
- openRxiv
- Published
- 2019-05-17
- Volume
- 18
- Pages
- 98-118
- ISSN
- 2329-0501 (ISSN-L)
- PMC
- PMC7488757
- OpenAlex
- W3026609212
- Cited by
- 156
- References
- 71
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 27 · 2023: 28 · 2022: 24 · 2021: 23 · 2020: 7 · 2019: 1
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Howard Hughes Medical Institute
- Children's Hospital of Philadelphia
- University of Georgia
- National Institutes of Health (1s10od010786-01, HL51670, CA086862, DK54759)
- University of California, Davis
- University of California, San Francisco
- Holden Comprehensive Cancer Center, University of Iowa (P30-CA086862)
- National Heart, Lung, and Blood Institute (P01HL051670, U01HL145795, P01HL089707)
- National Cancer Institute (U01CA207702, P30CA086862)
- National Institute of General Medical Sciences (F32GM126663)
- National Institute of Allergy and Infectious Diseases (T32AI060537)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK107607, P30DK054759)
- National Institute of Environmental Health Sciences (U01ES032673)
- Genome Center, University of California, Davis (1S10OD010786-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus, transient transfection, post-translational modification, DNA methylation, vector immunogenicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.